Media - Abzena


MHC Associated Peptide Proteomics

Case Study MAPPs for Vaccine Design To identify MHC class I presented antigens derived from influenza strain H1N1, two[...]



Abzena’s Biopharmaceutical Discovery & Development Symposium

26 April 2018

Abzena are hosting the first Biopharmaceutical Discovery & Development Symposium to showcase the latest technologies[...] Read more

World ADC Europe

26 March 2018

This is the 8th staging of Europe’s leading antibody-drug conjugation conference. The meeting is Europe’s leading[...] Read more


Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids

Natural products have been used for many medicinal purposes for centuries. Antibody drug conjugates (ADCs) have utilized[...] Read more


Abzena strengthens specialized bioassay offering through access agreement with major cell line depository

Cambridge, UK, 13 March 2018 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group[...] Read more

Abzena takes on new facilities in Cambridge, UK and San Diego

Cambridge, UK 5 January 2018 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group[...] Read more


We’re changing the way we brand our businesses

To provide our Partners with a single identity for the services and technologies offered across Antitope, PacificGMP,[...] Read more

Interested in our services? Get In Touch